Literature DB >> 19601836

ADAM28 as a target for human cancers.

Satsuki Mochizuki1, Yasunori Okada.   

Abstract

ADAM28 is a member of the ADAM (a disintegrin and metalloproteinase) gene family and consists of two isoforms, prototype membrane-type form and short secreted form. The metalloproteinase domain of ADAM28 has the zinc-binding consensus sequence, and ADAM28 exhibits catalytic activity to a few substrates such as insulin-like growth factor binding protein-3. The disintegrin domain interacts with integrins alpha4beta1, alpha4beta7 and alpha9beta1. In human non-small cell lung carcinomas and breast carcinomas, ADAM28 is overexpressed predominantly by carcinoma cells, and the expression correlates with carcinoma cell proliferation and lymph node metastasis. In this review we present our data on the activation of proADAM28, the tissue localization in human cancers and the interaction molecules, and discuss the regulation of ADAM28 activity and gene expression, the functions of ADAM28 in human cancers and the possibility of ADAM28 as a target for cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601836     DOI: 10.2174/138161209788682424

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Homozygous loss of ADAM3A revealed by genome-wide analysis of pediatric high-grade glioma and diffuse intrinsic pontine gliomas.

Authors:  Jennifer Barrow; Martyna Adamowicz-Brice; Maria Cartmill; Donald MacArthur; James Lowe; Keith Robson; Marie-Anne Brundler; David A Walker; Beth Coyle; Richard Grundy
Journal:  Neuro Oncol       Date:  2010-12-07       Impact factor: 12.300

2.  A proteomic approach for identification and localization of the pericellular components of chondrocytes.

Authors:  Zijun Zhang; Wu Jin; Jeffrey Beckett; Thomas Otto; Berton Moed
Journal:  Histochem Cell Biol       Date:  2011-06-23       Impact factor: 4.304

Review 3.  The ADAMs family of proteases as targets for the treatment of cancer.

Authors:  Maeve Mullooly; Patricia M McGowan; John Crown; Michael J Duffy
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

4.  Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.

Authors:  Li Wei; Jing-Yun Wen; Jie Chen; Xiao-Kun Ma; Dong-Hao Wu; Zhan-Hong Chen; Jiang-Long Huang
Journal:  World J Gastroenterol       Date:  2019-10-07       Impact factor: 5.742

5.  VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.

Authors:  Hiroaki Takaya; Tadashi Namisaki; Mitsuteru Kitade; Kosuke Kaji; Keisuke Nakanishi; Yuki Tsuji; Naotaka Shimozato; Kei Moriya; Kenichiro Seki; Yasuhiko Sawada; Soichiro Saikawa; Shinya Sato; Hideto Kawaratani; Takemi Akahane; Ryuichi Noguchi; Masanori Matsumoto; Hitoshi Yoshiji
Journal:  BMC Gastroenterol       Date:  2019-10-21       Impact factor: 3.067

6.  MicroRNA-552 enhances metastatic capacity of colorectal cancer cells by targeting a disintegrin and metalloprotease 28.

Authors:  Jian Wang; Hai Li; Yong Wang; Libin Wang; Xiurui Yan; Dong Zhang; Xiaoqiang Ma; Yong Du; Xiaoming Liu; Yinxue Yang
Journal:  Oncotarget       Date:  2016-10-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.